Patent DE1143937B successfully refreshed from Google Patents.
← Back to Patent Explorer
US4642120A Expired / Lapsed US ⏱️ 0.0 years remaining

Repair of cartilage and bones

Assignee: Ramot at Tel Aviv University Ltd
•
Filing: 1984-03-21
•
Granted: 1987-02-10
•
Expires: 2004-03-21
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract There are provided compositions for repairing defects of cartilage and bones. These are provided in gel form either as such, or embedded in natural or artificial bones. The gel comprises certain types of cells. These may be committed embryonal chondocytes or any kind of mesenchyme originated cells which potentially can be converted to cartilage cells, generally by the influence of chondrogenic inducing factors, in combination with fibrinogen, antiprotease and thrombin. The cells ought to be of the species to which the composition is transplanted. It is advantageous to incorporate in the gel extracellular matrix (ECM) of chondrocytes or other hormones and/or growth factors such as SM (Somatomedin=IGF-I), FGF (fibroblast growth factor), CGF (cartilage growth factor), BDGF (bone derived growth factor) or a combination of any of these.

Inventors

  • 👤 Zvi Nevo
  • 👤 Samuel Itay

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-22 17:14
CPC Classifications
C; C12; C12N; C12N5/00; C12N5/06; C12N5/0602; C12N5/0652; C12N5/0655; A; A61; A61F; A61F2/00; A61F2/02; A61F2/30; A61F2/30756; A61K; A61K35/00; A61K35/12; A61K35/14; A61K35/32; A61K35/48; A61K35/54; A61K38/00; A61K38/16; A61K38/43; A61K38/46; A61K38/48; A61L; A61L24/00; A61L24/04; A61L24/10; A61L24/106; A61L27/00; A61L27/36; A61L27/38; A61L27/3804; A61L27/3817; C12N5/0068; A61F2/28; A61F2002/2817; A61F2310/00; A61F2310/00005; A61F2310/00359; A61L2430/00; A61L2430/02; A61L2430/06; C12N2500/00; C12N2500/30; C12N2500/38; C12N2501/00; C12N2501/70; C12N2533/00; C12N2533/50; C12N2533/56; C12N2533/90

Claims Analysis

Total Claims: 9
Claim 1
Independent Claim 61 words
A composition of the repair of defects of articular cartilage and bones by implantation, comprising: cells selected from the group consisting of embryonal chondrocytes, and mesenchyme cells of the species to which the composition is to be implanted capable of being converted by chondrogenic inducing factors to cartilage cells, and a biological glue consisting of fibrinogen, thrombin and a protease inhibitor.
Claim 2
Dependent Claim 61 words
A composition of the repair of defects of articular cartilage and bones by implantation, comprising: cells selected from the group consisting of embryonal chondrocytes, and mesenchyme cells of the species to which the composition is to be implanted capable of being converted by chondrogenic inducing factors to cartilage cells, and a biological glue consisting of fibrinogen, thrombin and a protease inhibitor.
Claim 3
Dependent Claim 17 words
The composition according to claim 1, containing from 100,000 to 500,000 chondrocytes or mesenchyme cells per milliliter.
Claim 4
Dependent Claim 18 words
The composition according to claim 1, wherein the chondrocytes comprise from 5 to 20 mg/ml extracellular matrix (ECM).
Claim 5
Dependent Claim 16 words
The composition according to claim 1, further comprising a local growth factor or a hormonal-growth factor.
Claim 6
Dependent Claim 23 words
The composition according to claim 4, wherein the local growth factor is cartilage derived growth factor (CDF) or bone derived growth factor (BDGF).
Claim 7
Dependent Claim 23 words
The composition according to claim 4, wherein the hormonal growth factor is somatomedin selected from the group consisting of serum and pituitary somatomedin.
Claim 8
Dependent Claim 37 words
The composition according to claim 1, wherein the cells are chondrocytes or cells derived from connective tissue containing undifferentiated mesenchyme trapped, cells which are capable of being induced in culture to proliferate and be converted into chondrocytes.
Claim 9
Dependent Claim 14 words
The composition of claim 1 wherein the protease inhibitor is a natural protease inhibitor.

References Cited (Backward Citations)

JPS5836545A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1990-02-09 1990-08-11 1991-02-10 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1994-02-09 1994-08-11 1995-02-10 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1998-02-09 1998-08-11 1999-02-10 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag